研發台灣膽道癌專屬免疫化療複方(NGS) 降低副作用 整體存活期延長至19個月
改良型GS處方研究論文已發表於知名國際期刊《Liver International》,NGS處方初步成果已發表於2021年歐洲臨床腫瘤學會(ESMO)胃腸腫瘤年會。
改良型GS處方研究論文已發表於知名國際期刊《Liver International》,NGS處方初步成果已發表於2021年歐洲臨床腫瘤學會(ESMO)胃腸腫瘤年會。
Oral cancer is a major public health problem in Taiwan. It is largely attributable to the widespread areca nut and betel quid chewing habit. Based on national health surveys, the betel quid chewing rates in Taiwan have declined since 2007.
NHRI has established a novel chemotherapy regimen, SLOG, with promising activity and safety profiles in the treatment of metastatic pancreatic cancer.
The result of TCOG T1211 SLOG study was published in European Journal of Cancer (https://www.ejcancer.com/article/S0959-8049(19)30795-6/fulltext).
The NICR published the research result of “The Influence of Alcohol on the Risk and Survival of Head and Neck Cancer
” (Sci Rep. 2017 Aug 29;7(1):9701). The article was reported in No. 819 of NHRI Communications (Chinese Version).
NICR established the Cell-based Therapeutic Unit in collaboration with the National Cheng Kung University Hospital on Sep. 26, 2019. The article was reported in No. 812 of NHRI Communications (Chinese Version).
The NICR published the research result of “Nanoliposomal irinotecan with 5-fluorouracil and leucovorin in metastatic pancreatic cancer after prior gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label phase 3 trial. ” (Lancet 2016 Feb;387(10018):545-57). The article was reported in No. 631 of NHRI Communications (Chinese Version).